目前,玻璃体腔注射抗血管内皮生长因子(VEGF)药物已成为治疗视网膜血管性疾病相关黄斑水肿的标准方案。单纯抗VEGF药物治疗存在治疗效果的差异化、疗效持续性不足、治疗负担重等局限性。作为眼科首个双特异性抗体药物,Faricimab通过同时靶向VEGF-A和血管生成素-2(Ang-2)双通路,取得了良好的疗效。难治性黄斑水肿患眼经Faricimab治疗后,超过 2/3既往治疗无效的患眼视力得到改善。因此,Faricimab对治疗DME、RVO-ME、AMD以及其他难治性ME具有重要的临床意义。本文对Faricimab的作用机制、临床研究及最新研究成果进行了系统性综述。

At present, intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs has become the standard treatment for macular edema associated with retinal vascular disease. The use of anti-VEGF drugs alone has limitations such as differential therapeutic effects, insufficient persistence of efficacy, and heavy treatment burden. As the first bispecific antibody drug in ophthalmology, Faricimab has achieved good therapeutic effects by targeting both VEGF-A and angiopoietin-2 (Ang-2) pathways simultaneously. After treatment with Faricimab, more than 2/3 of the eyes with refractory macular edema showed improvement in vision despite previous ineffective treatments. Therefore, Faricimab has important clinical significance in the treatment of DME, RVO-ME, AMD, and other refractory ME. This article systematically reviews the mechanism of action, clinical studies, and the latest research findings of Faricimab.

滨州医学院科技计划项目(BY2020KJ56)；山东省医药卫生科技发展计划项目(2019WS333)；滨州医学院教学改革与研究立项项目(JYKTLX202284)